Latest News - ResMed
Top Corporates Hub
ResMed
If EPS Growth Is Important To You, ResMed (NYSE:RMD) Presents An Opportunity
16.02.2026 13:00
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Invesco International Growth Fund Q4 2025 Portfolio Update
16.02.2026 11:43
Invesco International Growth Fund underperformed most in industrials, consumer discretionary and communication services, all due to stock selection. Read more here.
ResMed (RMD): Buy, Sell, or Hold Post Q4 Earnings?
16.02.2026 04:03
Over the past six months, ResMed’s shares (currently trading at $252.56) have posted a disappointing 11.7% loss, well below the S&P 500’s 5.9% gain. This might have investors contemplating their next move.
ResMed (RMD) Valuation Check After Strong Earnings And Dividend Update
12.02.2026 11:14
ResMed (RMD) is back in focus after reporting higher sales and net income for its second quarter and first half of fiscal 2026, alongside a fresh quarterly dividend declaration of $0.60 per share. See our latest analysis for ResMed. ResMed’s recent earnings and dividend news comes after a period of steadier trading, with a 90 day share price return of 2.98% and a 1 year total shareholder return of 10.96%. This suggests gradually building momentum rather than a sharp re rating. If this update...
Is It Time To Reassess ResMed (RMD) After Recent Medical Devices Sector Interest
12.02.2026 09:16
If you are wondering whether ResMed's current share price lines up with its underlying worth, you are not alone. That is exactly what this article will unpack for you. ResMed recently closed at US$259.62, with returns of 1.3% decline over 7 days, 0.7% over 30 days, 6.0% year to date, 11.0% over 1 year, 24.3% over 3 years, and 35.7% over 5 years. This gives investors a useful backdrop before comparing price to value. Recent news flow around ResMed has largely focused on ongoing interest in...
ResMed Deepens CPAP Lead As Wearables And Digital Tools Expand Reach
05.02.2026 06:11
ResMed (NYSE:RMD) is seeing growing use of wearable devices for sleep apnea pre screening, widening its reach before patients ever enter a sleep lab. Recent FDA approvals are supporting ResMed's role in sleep and respiratory care equipment. New drug therapies are expanding the potential patient pool that may still require CPAP support. Philips' ongoing CPAP recall continues to leave ResMed with a dominant share of the CPAP market. ResMed's digital ecosystem is playing a larger role in...
The Top 5 Analyst Questions From ResMed’s Q4 Earnings Call
05.02.2026 05:44
ResMed’s fourth quarter performance drew a positive market reaction, with management attributing the outperformance to strong global demand for its masks and devices, as well as continued growth in its digital health software. CEO Michael Farrell highlighted double-digit growth in the U.S. mask segment—supported by the launch of new fabric mask products and expansion of direct-to-consumer initiatives. Management also pointed to operational efficiencies, particularly in supply chain and manufactu
4 Medical Product Stocks to Watch From a Challenging Industry (Revised)
03.02.2026 10:37
The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
ResMed Inc. (RMD): A Bull Case Theory
03.02.2026 01:53
We came across a bullish thesis on ResMed Inc. on Best Anchor Stocks’s Substack. In this article, we will summarize the bulls’ thesis on RMD. ResMed Inc.’s share was trading at $257.61 as of January 29th. RMD’s trailing and forward P/E were 26.38 and 23.70 respectively according to Yahoo Finance. ResMed Inc. develops, manufactures, distributes, and markets […]
ResMed: Facing A Potentially Dream-Disrupting Dose - Strong Sell
01.02.2026 00:54
ResMed dominates the global sleep apnea device market, boasting a 50â60% share and a high-margin razor-razor-blade business model. See why RMD is a Strong Sell.
Horatio Alger Honor Puts ResMed Leadership And Growth Story In Focus
30.01.2026 07:09
ResMed founder Dr. Peter Farrell has received the Horatio Alger Award, recognizing his contributions to respiratory care and medical devices. The award highlights ResMed's role in addressing sleep apnea and other respiratory conditions through its therapies and digital health tools. This recognition brings added attention to NYSE:RMD at a time when the company’s share price is $257.61. For investors following NYSE:RMD, this award puts a spotlight on the company’s long-term presence in sleep...
ResMed Q2 Earnings Call Highlights
30.01.2026 06:36
ResMed (NYSE:RMD) executives highlighted revenue growth, margin expansion and continued investment in product development and demand-generation initiatives during the company’s second quarter fiscal 2026 earnings call. Management also discussed progress in its software portfolio, the company’s view
ResMed Inc (RMD) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations
30.01.2026 05:04
ResMed Inc (RMD) reports robust financial performance with 11% revenue growth and unveils new product launches amidst competitive market dynamics.
Stay Ahead of the Game With ResMed (RMD) Q2 Earnings: Wall Street's Insights on Key Metrics
27.01.2026 14:15
Besides Wall Street's top-and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
Dr. Peter Craig Farrell, Founder of ResMed, Inc., to Receive Prestigious 2026 Horatio Alger Award
27.01.2026 13:00
The Horatio Alger Association of Distinguished Americans, Inc., a nonprofit that honors leaders who have overcome adversity and supports young people in furthering their education, today announced that Dr. Peter Craig Farrell, Founder of ResMed, Inc., will receive the prestigious Horatio Alger Award and become a lifetime member of the organization. Farrell joins 10 other exceptional corporate, civic, and cultural leaders from across the country in the 2026 class of honorees. For the last 79 year
Resmed's Q2 Earnings on Deck: What's in Store for the Stock?
27.01.2026 12:54
RMD is set to report Q2 results on Jan. 29, with revenues likely to jump 8.3% and EPS 10.3% as masks, devices and software drive growth.
1 Safe-and-Steady Stock Worth Investigating and 2 We Find Risky
26.01.2026 04:35
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
ResMed Inc.'s (NYSE:RMD) Stock Has Fared Decently: Is the Market Following Strong Financials?
24.01.2026 11:00
ResMed's (NYSE:RMD) stock up by 3.2% over the past month. Given that the market rewards strong financials in the...
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
22.01.2026 15:00
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AdvaMed leaders on tariffs, MDUFA and wearables
22.01.2026 11:13
AdvaMed CEO Scott Whitaker and Mick Farrell, new board chair of the trade group, weighed in on important issues for the medtech industry one year into the Trump administration.